ARCHIVES

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

Cooperative Groups Pursue Contracts With Insurers, NCI Warns of Competition

June 14, 1996

Research Base Would Be Increased In Guideline Change

November 9, 1990

New Phone Number For Customer Service For The Cancer Letter

February 6, 1998

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

July 25, 2014

CTEP Deploys Website To Track Trial Activation

December 10, 2010

Blumenthal Says Action Plan To Issue “New Priority Areas”

October 24, 1996